Shield Post-Approval Study Protocol
← catalyst calendarNCT06880055 · readout in 1,474 d
Sponsored by Guardant Health, Inc. (industry) · GH — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
3,375estimated
Sites
69
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-14 | actual | When the study began enrolling |
| Primary completion | 2030-09-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-12-01 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Colo-rectal Cancer
Intervention
- Diagnostic test: Shield Blood Test for colo-rectal cancer Screening
Primary outcome
what the primary-completion date above is the date OFPerformance measures of the Shield test will be assessed for the second testing interval
measured 33-42 Months Post-Enrollment
Permalink · GH's whole pipeline · Catalyst calendar · Every registered study · What changed